.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
US Department of Justice
Express Scripts
Fish and Richardson
Chinese Patent Office
UBS
Julphar
Citi
Deloitte

Generated: July 24, 2017

DrugPatentWatch Database Preview

NIRAVAM Drug Profile

« Back to Dashboard

What is the patent landscape for Niravam, and what generic Niravam alternatives are available?

Niravam is a drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in nine countries.

The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the alprazolam profile page.

Summary for Tradename: NIRAVAM

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list34
Clinical Trials: see list3
Patent Applications: see list8,994
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NIRAVAM at DailyMed

Pharmacology for Tradename: NIRAVAM

Ingredient-typeBenzodiazepines
Drug ClassBenzodiazepine
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-001Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-004Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-002Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-004Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-001Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NIRAVAM

Drugname Dosage Strength RLD Submissiondate
alprazolamOrally Disintegrating Tablets0.25 mg, 0.5 mg, 1 mg and 2 mgNiravam12/27/2005

International Patent Family for Tradename: NIRAVAM

Country Document Number Estimated Expiration
European Patent Office0975336► Subscribe
European Patent Office2266538► Subscribe
European Patent Office2147669► Subscribe
Australia6896998► Subscribe
Canada2284663► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Daiichi Sankyo
Baxter
Merck
Fish and Richardson
McKinsey
Citi
Chubb
Argus Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot